Note: This document contains side effect information about bisoprolol. Some dosage forms listed on this page may not apply to the brand name Zebeta.

Summary

More frequent side effects include: fatigue. Continue reading for a comprehensive list of adverse effects.

Applies to bisoprolol: oral tablets.

Side effects include:

Fatigue, headache, diarrhea, peripheral edema, and upper respiratory tract infection.

For Healthcare Professionals

Applies to bisoprolol: oral tablet.

General

The more commonly reported side effects observed with this drug are bradycardia, dizziness, and hypotension.^[Ref]

Cardiovascular

Very common (10% or more): Bradycardia (up to 15.2%)

Common (1% to 10%): Chest pain, heart failure aggravation, hypotension, cold extremities, peripheral edema, ischemia, conduction disorder, left cardiac failure, palpitation, vein disorder

Uncommon (0.1% to 1%): Atrioventricular (AV) disturbances, orthostatic hypotension

Frequency not reported: Other rhythm disturbances, claudication^[Ref]

Bradycardia occurred as a dose-related event.

Cardiac failure occurred in 18.4% of patients (n=1328) compared with 22.8% of placebo-treated patients (n=1321).^[Ref]

Nervous system

Very common (10% or more): Dizziness (up to 13.3%)

Common (1% to 10%): Headache, extremity numbness, cerebrovascular disorder, syncope, hypoesthesia

Frequency not reported: Vertigo, paresthesia, hypoesthesia, hyperesthesia, somnolence, decreased concentration/memory, tremor, taste abnormalities

Postmarketing reports: Unsteadiness^[Ref]

Respiratory

Very common (10% or more): Dyspnea (up to 13.8%)

Common (1% to 10%): Pneumonia, bronchitis, coughing, exertional dyspnea, upper respiratory tract infection, respiratory distress, stridor, respiratory tract edema, respiratory tract hemorrhage, sinusitis

Uncommon (0.1% to 1%): Bronchospasm

Rare (0.01% to 0.1%): Allergic rhinitis^[Ref]

Sinusitis occurred as a dose-related event.^[Ref]

Immunologic

Very common: Antinuclear antibody (ANA) conversions (up to 15%)

Common (1% to 10%): Viral infection^[Ref]

Dermatologic

Common (1% to 10%): Pruritus

Uncommon (0.1% to 1%): Sweating

Rare (0.01% to 0.1%): Itching, flushing, rash

Very rare (less than 0.01%): Alopecia, psoriasis-like rash, psoriasis exacerbation

Frequency not reported: Acne, eczema, skin irritation, cutaneous vasculitis

Postmarketing reports: Dermatitis, exfoliative dermatitis^[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, vomiting, diarrhea, constipation, dyspepsia, epigastric pain (not food related), abdominal pain, gastritis, dry mouth

Frequency not reported: Gastric pain, peptic ulcer^[Ref]

Diarrhea occurred as a dose-related event.^[Ref]

Metabolic

Uric acid, serum potassium, glucose, and phosphorus increases associated with use of this drug were not of clinical importance and rarely resulted in discontinuation.^[Ref]

Common (1% to 10%): Purine metabolism disorder, carbohydrate metabolism disturbed, weight changes, cholesterol changes, potassium levels altered, blood lipid changes

Rare (0.01% to 0.1%): Increased triglycerides

Frequency not reported: Gout

Postmarketing reports: Increased uric acid and glucose^[Ref]

Musculoskeletal

Common (1% to 10%): Limb pain, myalgia, arthropathy, arthralgia

Uncommon (0.1% to 1%): Muscular weakness, cramps

Frequency not reported: Back pain, neck pain, twitching^[Ref]

Other

Fatigue and asthenia occurred as dose-related events.^[Ref]

Common (1% to 10%): Asthenia, fatigue, body pain, fever, malaise

Rare (0.01% to 0.1%): Hearing disorders

Frequency not reported: Earache, tinnitus^[Ref]

Psychiatric

Common (1% to 10%): Insomnia, anxiety

Uncommon (0.1% to 1%): Sleep disorders, depression

Rare (0.01% to 0.1%): Nightmares, hallucinations

Frequency not reported: Restlessness^[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection

Rare (0.01% to 0.1%): Potency disorders

Frequency not reported: Decreased libido, Peyronie's disease, polyuria^[Ref]

Hepatic

Transaminase elevations of 1 to 2 times the upper limit of normal were reported in 6.2% of patients, with a multiple occurrence rate of 1.9%. Generally, this increase was the result of underlying disorders or resolved with continued use of this drug.^[Ref]

Common (1% to 10%): Hepatomegaly

Rare (0.01% to 0.1%): Increased liver enzymes (ALT, AST), hepatitis^[Ref]

Hypersensitivity

Rare (0.01% to 0.1%): Hypersensitivity

Postmarketing reports: Angioedema^[Ref]

Of the 15% of patients who developed positive ANA status, one-third of patients converted back to a negative titer with continued use.^[Ref]

Ocular

Rare (0.01% to 0.1%): Reduced tear flow

Very rare (less than 0.01%): Conjunctivitis

Frequency not reported: Visual disturbances, ocular pain, ocular pressure^[Ref]

Renal

Creatinine and BUN were associated with slightly increased levels, but these effects were generally not of clinical importance and rarely resulted in discontinuation.^[Ref]

Frequency not reported: Cystitis, renal colic

Postmarketing reports: Increased creatinine and BUN^[Ref]

Hematologic

Postmarketing reports: Purpura, decreases in WBC and platelets^[Ref]

During treatment with this drug, decreased levels of WBCs and platelets were not of clinical importance and rarely resulted in discontinuation.^[Ref]